Probiotics in the prevention of colorectal cancer

Current Colorectal Cancer Reports

Volumn 9, Issue 1, 2013, Pages 31-36

  Shmuely, Haim ^a   Domniz, Noam ^a   Cohen, Dani ^b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Animal models; Colorectal cancer; Human studies; Prevention of cancer; Probiotics

Indexed keywords

CYTOCHROME P450 1A1; CYTOCHROME P450 2E1; CYTOCHROME P450 3A; CYTOCHROME P450 3A9; INULIN; PREBIOTIC AGENT; PROBIOTIC AGENT; SULINDAC; UNCLASSIFIED DRUG; VSL3; YOGHURT;

ADENOMATOUS POLYP; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BACTERIAL STRAIN; BIFIDOBACTERIUM BREVE; BIFIDOBACTERIUM LONGUM; BIFIDOBACTERIUM LONGUM INFANTIS; CANCER INHIBITION; CANCER PREVENTION; CELL PROLIFERATION; COLON CARCINOGENESIS; COLON POUCH; COLORECTAL ADENOMA; COLORECTAL CANCER; COLORECTAL CARCINOMA; DETOXIFICATION; DIET SUPPLEMENTATION; DNA DAMAGE; DRUG EFFECT; DRUG EFFICACY; FAMILIAL DISEASE; HUMAN; IMMUNOMODULATION; INTERVENTION STUDY; INTESTINE ANASTOMOSIS; INTESTINE FLORA; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS BULGARICUS; LACTOBACILLUS CASEI; LACTOBACILLUS PLANTARUM; MICROBIOME; NONHUMAN; PROCTOCOLECTOMY; PROTEIN EXPRESSION; STREPTOCOCCUS THERMOPHILUS;

EID: 84873722699     PISSN: 15563790     EISSN: 15563804     Source Type: Journal    
DOI: 10.1007/s11888-012-0153-2     Document Type: Article

References (52)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;15:2893-917.
3. Senter L. Genetic testing by cancer site: colon (nonpolyposis syndromes). Cancer J. 2012;18:334-7.
4. Kaz AM, Brentnall TA. Genetic testing for colon cancer. Nat Clin Pract Gastroenterol Hepatol. 2006;3:670-9.
5. Ries LA, Wingo PA, Miller DS, et al. The annual report to the nation on the status of cancer, 1973-1997, with a special section on colorectal cancer. Cancer. 2000;88:2398-424.
6. Rowland I. Gut microflora and cancer. In: Leeds AR, Rowland IR, editors. Gut flora and health-past, present and future. London: Royal Society of Medicine; 1996. p. 19-25.
7. De Preter V, Hamer HM, Windey K, Verbeke K. The impact of pre- and/or probiotics on human colonic metabolism: does it affect human health? Mol Nutr Food Res. 2011;55:46-57.
8. Orrhage K, Nord CE. Bifidobacteria and lactobacilli in human health. Drugs Exp Clin Res. 2000;26:95-111.
9. Fernández L, Langa S, Martín V, et al. The human milk microbiota: origin and potential roles in health and disease. Pharmacol Res. 2012. doi: 10.1016/j.phrs.2012.09.001.
10. Pool-Zobel BL, Neudecke C, Domizlaff I, et al. Lactobacillus- and Bifidobacterium-mediated antigenotoxicity in the colon of rats. Nutr Cancer. 1996;26:365-80.
11. • Friederich P, Verschuur J, van Heumen BW, et al. Effects of intervention with sulindac and inulin/VSL#3 on mucosal and luminal factors in the pouch of patients with familial adenomatous polyposis. Int J Colorectal Dis. 2011;26:575-82. This intervention study in patients with FAP showed decreased cell proliferation and increased detoxification capacity (albeit not statistical significant) after treatment with sulindac or VSL#3/inulin; combining both regimens did not show an additional effect on carcinogenesis.
12. Toprak NU, Yagci A, Gulluoglu BM, et al. A possible role of Bacteroides fragilis enterotoxin in the aetiology of colorectal cancer. Clin Microbiol Infect. 2006;12:782-6.
13. Wu S, Morin PJ, Maouyo D, Sears CL. Bacteroides fragilis enterotoxin induces c-Myc expression and cellular proliferation. Gastroenterology. 2003;124:392-400.
14. Wu S, Rhee KJ, Albesiano E, et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med. 2009;15:1016-22.
15. Chung GT, Franco AA, Wu S, et al. Identification of a third metalloprotease toxin gene in extraintestinal isolates of Bacteroides fragilis. Infect Immun. 1999;67:4945-9.
16. Franco AA, Mundy LM, Trucksis M, Wu S, Kaper JB, Sears CL. Cloning and characterization of the Bacteroides fragilis metalloprotease toxin gene. Infect Immun. 1997;65:1007-13.
17. Kato N, Liu CX, Kato H, et al. A new subtype of the metalloprotease toxin gene and the incidence of the three bft subtypes among Bacteroides fragilis isolates in Japan. FEMS Microbiol Lett. 2000;182:171-6.
18. •• Odamaki T, Sugahara H, Yonezawa S. Effect of the oral intake of yogurt containing Bifidobacterium longum BB536 on the cell numbers of enterotoxigenic Bacteroides fragilis in microbiota. Anaerobe. 2012;18:14-8. This is a well-designed open, randomized, parallel-group human study indicating the potential effect of probiotic yogurt in eliminating ETBF colonization found to be associated with CRC.
19. Pozza A, Scarpa M, Ruffolo C, et al. Colonic carcinogenesis in IBD: Molecular events. Ann Ital Chir. 2011;82:19-28.
20. Marnett LJ. Inflammation and cancer: chemical approaches to mechanisms, imaging, and treatment. J Org Chem. 2012;77:5224-38.
21. Bibiloni R, Fedorak RN, Tannock GW, et al. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol. 2005;100:1539-46.
22. Ng SC, Plamondon S, Kamm MA, et al. Immunosuppressive effects via human intestinal dendritic cells of probiotic bacteria and steroids in the treatment of acute ulcerative colitis. Inflamm Bowel Dis. 2010;16:1286-98.
23. Wang X, O'Gorman MR, Bu HF, Koti V, Zuo XL, Tan XD. Probiotic preparation VSL#3 alters the distribution and phenotypes of dendritic cells within the intestinal mucosa in C57BL/10 J mice. J Nutr. 2009;139:1595-602.
24. Rafter J. The effects of probiotics on colon cancer development. Nutr Res Rev. 2004;17:277-84.
25. Appleyard CB, Cruz ML, Isidro AA, Arthur JC, Jobin C, De Simone C. Pretreatment with the probiotic VSL#3 delays transition from inflammation to dysplasia in a rat model of colitis-associated cancer. Am J Physiol Gastrointest Liver Physiol. 2011;301:G1004-13.
26. Sood A, Midha V, Makharia GK, et al. The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clin Gastroenterol Hepatol. 2009;7:1202-9.
27. Hofmanová J, Ciganek M, Slavík J, et al. Lipid alterations in human colon epithelial cells induced to differentiation and/or apoptosis by butyrate and polyunsaturated fatty acids. J Nutr Biochem. 2012;23:539-48.
28. • Bassaganya-Riera J, Viladomiu M, Pedragosa M, De Simone C, Hontecillas R. Immunoregulatory mechanisms underlying prevention of colitis-associated colorectal cancer by probiotic bacteria. PLoS One. 2012;7:e34676. This study describes the effect of combining probiotics and polyunsaturated fatty acid in diminishing adenoma and adenocarcinoma formation.
29. Ivanov II, Littman DR. Segmented filamentous bacteria take the stage. Mucosal Immunol. 2010;3:209-12.
30. Bulow S, Alm T, Fausa O, Hultcrantz R, Jarvinen H, Vasen H. Duodenal adenomatosis in familial adenomatous polyposis: DAF profect group. Int J Colorectal Dis. 1995;10:43-6.
31. Vasen HFA, Duijvendijk P, Buskens E, et al. Decision analysis in the surgical treatment of patients with familial adenomatous polyposis: A Dutch-Scandinavian collaborative study including 659 patients. Gut. 2001;49:231-5.
32. Roberfroid M. Prebiotics: the concept revisited. J Nutr. 2007;137 Suppl 2:S830-7.
33. Demarzo MM, Garcia SB. Exhaustive physical exercise increases the number of colonic preneoplastic lesions in untrained rats treated with a chemical carcinogen. Cancer Lett. 2004;216:31-4.
34. Wargovich MJ, Chen CD, Harris C, Yang E, Velasco M. Inhibition of aberrant crypt growth by non-steroidal anti-inflammatory agents and differentiation agents in the rat colon. Int J Cancer. 1995;60:515-19.
35. Chang JH, Shim YY, Cha SK, Reaney MJ, Chee KM. Effect of Lactobacillus acidophilus KFRI342 on the development of chemically induced precancerous growths in the rat colon. J Med Microbiol. 2012;61:361-8.
36. Chang J-H, Shim YY, Cha S-K, et al. Probiotic characteristics of lactic acid bacteria isolated from kimchi. J Appl Microbiol. 2010;109:220-30.
37. •• Foo NP, Ou Yang H, Chiu HH, Chan HY, Liao CC, Yu CK, Wang YJ. Probiotics prevent the development of 1, 2-dimethylhydrazine (DMH)-induced colonic tumorigenesis through suppressed colonic mucosa cellular proliferation and increased stimulation of macrophages. J Agric Food Chem. 2011;59:13337-45. This provides important information for every cancer researcher showing that dietary consumption of probiotics significantly inhibits initial colon cancer cell growth in a CRC model.
38. Pool-Zobel BL, Neudecker C, Domizlaff I, et al. Lactobacillus- and bifidobacterium-mediated antigenotoxicity in the colon of rats. Nutr Cancer. 1996;26:365-80.
39. Jin JQ, Hu YY, Niu YM, et al. CYP1A1 Ile462Val polymorphism contributes to colorectal cancer risk: a meta-analysis. World J Gastroenterol. 2011;17:260-6.
40. Zhou GW, Hu J, Li Q. CYP2E1 PstI/RsaI polymorphism and colorectal cancer risk: a meta-analysis. World J Gastroenterol. 2010;16:2949-53.
41. Mei N, Guo L, Liu R, Fuscoe JC, Chen T. Gene expression changes induced by the tumorigenic pyrrolizidine alkaloid riddelliine in liver of Big Blue rats. BMC Bioinforma. 2007;8 Suppl 7:S4.
42. Matuskova Z, Siller M, Tunkova A, et al. Effects of Lactobacillus casei on the expression and the activity of cytochromes P450 and on the CYP mRNA level in the intestine and the liver of male rats. Int J Immunopathol Pharmacol. 2011;1(Suppl):45S-50S.
43. Matuskova Z, Tunkova A, Anzenbacherova E, et al. Effects of probiotic Escherichia coli Nissle 1917 on expression of cytochromes P450 along the gastrointestinal tract of male rats. Euro Endocrinol Lett. 2010;31 Suppl 2:46-50.
44. Butler LM, Hewett PJ, Fitridge RA, et al. Deregulation of apoptosis in colorectal carcinoma: theoretical and therapeutic implications. Aust N Z J Surg. 1999;69:88-94.
45. Chen CC, Lin WC, Kong MS. Oral inoculation of probiotics Lactobacillus acidophilus NCFM suppresses tumour growth both in segmental orthotopic colon cancer and extra-intestinal tissue. Br J Nutr. 2012;107:1623-34.
46. Plotnikov A, Tichler T, Korenstein R, et al. Involvement of the immune response in the cure of metastatic murine CT-26 colon carcinoma by low electric field-enhanced chemotherapy. Int J Cancer. 2005;117:816-24.
47. Cho KH, Lee HS, Ku SK, et al. Decrease in intestinal endocrine cells in Balb/c mice with CT-26 carcinoma cells. J Vet Sci. 2008;9:9-14.
48. Vannucci L, Stepankova R, Grobarova V, et al. Colorectal carcinoma: importance of colonic environment for anti-cancer response and systemic immunity. J Immunotoxicol. 2009;6:217-26.
49. Mylonaki M, Rayment NB, Rampton DS, Hudspith BN, Brostoff J. Molecular characterization of rectal mucosa-associated bacterial flora in inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:481-7.
50. Bullock NR, Booth JC, Gibson GR. Comparative composition of bacteria in the human intestinal microflora during remission and active ulcerative colitis. Curr Issues Intest Microbiol. 2004;5:59-64.
51. •• Håkansson A, Bränning C, Molin G, et al. Blueberry husks and probiotics attenuate colorectal inflammation and oncogenesis, and liver injuries in rats exposed to cycling DSS-treatment. PLoS One. 2012;7:e33510. This is a well-designed study relating to dietary options of combining a probiotic mixture with blueberry husks in order to delay colonic carcinogenesis and hepatic injuries in induced colorectal tumors.
52. Yi WG, Fischer J, Krewer G, Akoh CC. Phenolic compounds from blueberries can inhibit colon cancer cell proliferation and induce apoptosis. J Agric Food Chem. 2005;53:7320-9.